1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Rekvina Laboratories Ltd.

Rekvina Laboratories Ltd.

BBSE:VINRKLB
55.34
INR
-2.91
(-5.00%)
-0.57EPS
206.66MMarket Cap
Rekvina Laboratories Ltd.
BSE:VINRKLB
(Bombay Stock Exchange)

Recent

price

55.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
0.12
0.11
0.13
0.05
0.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.09
3.25
Revenue per Share
-0.01
0.02
0.02
0.04
0.01
-0.09
-0.03
-0.13
-0.42
- -
-0.11
-0.13
- -
-0.03
-0.23
-0.42
-0.57
Basic EPS, GAAP
- -
- -
- -
-0.03
-0.04
-0.07
0.02
-0.04
0.14
-0.02
-0.01
-0.07
0.02
-0.01
-0.32
-0.98
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.04
1.06
1.09
1.13
0.93
0.84
0.81
0.67
0.26
0.26
0.15
0.02
0.02
-0.32
-0.55
-2.04
- -
Book Value per Share
1.04
1.06
1.09
1.13
0.93
0.84
0.81
0.67
0.26
0.26
0.15
0.02
0.02
-0.32
-0.55
-2.04
- -
Tangible Book Value per Share
6
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Basic Weighted Avg Shares
- -
1
1
1
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
13
19
Sales/Revenue/Turnover
- -
38.62
26.24
35.9
15.4
-89.81
- -
- -
- -
- -
- -
- -
- -
- -
- -
-20.13
-17.6
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
-1
- -
-1
-3
- -
-1
-1
- -
- -
-1
-3
-3
Net Income, GAAP
- -
- -
18.72
19.42
18.51
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
19.51
21.21
28.84
12.19
-89.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
-20.13
-17.58
Profit Margin (%)
3
3
3
3
3
3
3
2
-1
-1
-1
-2
-2
-2
-3
-12
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
6
6
7
7
6
5
5
4
2
2
1
- -
- -
-2
-3
-12
- -
Total Equity
- -
2.5
2.6
3.34
0.64
- -
- -
- -
- -
-94.3
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
4.94
2.62
3.34
0.65
- -
- -
- -
- -
1.54
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-1.28
2.5
2.6
3.34
0.64
-10.6
-3.89
-17.91
-89.63
1.54
-51.4
-147.84
-5.16
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
15
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
- -
218
207

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
12
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
6
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
24
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
15
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-145.05%
-265.81%
269.72%
Free Cash Flow
138.28%
487.73%
209.69%
Net Income, GAAP
57.51%
597.68%
85.78%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
2
3
7
13
2027
7
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.01
-0.11
-0.04
-0.07
-0.23
2026
-0.06
-0.06
-0.21
-0.1
-0.42
2027
-0.2
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Rekvina Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of finished dosage formulations and generic pharmaceutical products. The company operates across various therapeutic categories, offering a diversified portfolio comprising anti-infectives and antibacterial medications; analgesics, antipyretics, and anti-inflammatory drugs; respiratory and cough-and-cold treatments; gynecological and obstetrics preparations; gastrointestinal agents and antiemetics; antidiabetic therapies; dermatological topicals; and nutritional supplements. Its product line encompasses multiple formulation types, including solid oral dosage forms such as tablets (marketed under brand names including Aarther P, Astanol, Cedro CF, Fenmol, Megestone, Rekcin, Rekfa, Sugamet-GP2, and Vagi CL) and capsules (including Doxyrek, Miomycin, and Molox); liquid orals and pediatric suspensions such as Rekof syrup, Vegas syrup, and Rekoryl oral drops; dry syrups for antibiotic reconstitution; sterile injectable formulations such as Dispar, Gotrin, Rekseal, and Vomirek; and external topical preparations including Megaspan cream and Vagi cream. Rekvina Laboratories distributes its formulations to retail pharmacies, hospitals, distributors, and healthcare institutions primarily across India. Founded in November 1988, the company is headquartered in Vadodara, Gujarat, India, with its equity shares listed on the BSE under the ticker symbol VINRKLB. In recent corporate developments, the company underwent a major change in control and ownership restructuring following a Share Exchange and Purchase Agreement and a subsequent mandatory open offer concluded in July 2026, resulting in an acquirer group led by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel consolidating a 64.30% controlling stake to implement a strategic revival plan aimed at restarting scaled commercial operations and broadening pharmaceutical product lines. Furthermore, trading in the company's equity shares officially resumed on the BSE in January 2026 following the revocation of its previous trading suspension.